Skip to main content

Early-Onset Pediatric Atopic Dermatitis Tied to Higher Risk for Uveitis

Medically reviewed by Carmen Pope, BPharm. Last updated on April 23, 2025.

By Lori Solomon HealthDay Reporter

WEDNESDAY, April 23, 2025 -- Children with early-onset atopic dermatitis (AD) have an elevated risk for pediatric uveitis, according to a study published online April 3 in JAMA Ophthalmology.

Yung-Yu Chu, M.D., from Chi Mei Medical Center in Tainan City, Taiwan, and colleagues assessed whether the risk for pediatric uveitis is increased in children with early-onset AD versus a matched control population. The analysis included 114,889 patients with early-onset AD and 114,889 propensity score-matched controls without AD.

The researchers found that the AD cohort had a higher risk for developing pediatric uveitis versus controls (0.08 versus 0.05 percent; hazard ratio, 1.92). Similar results were seen among patients without dupilumab use (0.08 versus 0.05 percent; hazard ratio, 1.77) and those without autoimmune conditions (0.07 versus 0.05 percent; hazard ratio, 1.52). Patients with severe AD had a higher risk for developing pediatric uveitis versus those with nonsevere AD (0.40 versus 0.08 percent; hazard ratio, 3.64).

"This cohort study of children with early-onset AD found an elevated risk of pediatric uveitis compared with matched controls, independent of autoimmune conditions or dupilumab use," the authors write. "These findings support the potential need to consider ophthalmologic monitoring in children with early-onset AD to try to detect and subsequently manage uveitis if it develops."

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted April 2025

Read this next

American Academy of Dermatology, March 7 to 11

The annual meeting of the American Academy of Dermatology was held from March 7 to 11 in Orlando, Florida, and attracted clinicians, academicians, allied health...

AAD: Maintenance of Low Eczema Activity Seen After About 80 Days Off Tapinarof

FRIDAY, March 14, 2025 -- Patients with atopic dermatitis (AD) who achieve completely clear skin with tapinarof (Vtama) cream maintain low disease activity after about 80 days off...

Roflumilast Cream 0.05 Percent Safe, Effective in Young Children With Eczema

FRIDAY, March 14, 2025 -- Once-daily roflumilast cream 0.05 percent is safe and effective for atopic dermatitis (AD) in patients ages 2 to 5 years, according to a study...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.